Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.62 |
| ▸ | NPC1L1 | Q9UHC9 | 4/20 | 0.59 |
| ▸ | CDC25A | P30304 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | OSBP | P22059 | 2/20 | 0.54 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.54 |
| ▸ | CDC25B | P30305 | 1/20 | 0.54 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.53 |
| ▸ | FNTA | P49354 | 2/20 | 0.53 |
| ▸ | FNTB | P49356 | 2/20 | 0.53 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16225843 | 1.00 | CYP2D6 (0.63) | CYP2D6CYP2C19INPP5DNPC1L1CDC25A | |
| SCHEMBL16227067 | 1.00 | CYP2D6 (0.63) | CYP2D6CYP2C19INPP5DNPC1L1CDC25A | |
| SCHEMBL16906787 | 0.90 | OSBP (0.53) | CYP2D6CYP2C19INPP5DUSP2LMNA | |
| SCHEMBL9580263 | 0.89 | OSBP (0.53) | CYP2D6CYP2C19INPP5DNPC1L1CDC25A | |
| SCHEMBL23359045 | 0.89 | ST6GAL1 (0.51) | CYP2D6CYP2C19INPP5DNPC1L1CDC25A | |
| SCHEMBL6651462 | 0.89 | ST6GAL1 (0.51) | CYP2D6CYP2C19INPP5DNPC1L1CDC25A | |
| SCHEMBL22495528 | 0.89 | GPBAR1 (0.56) | CYP2D6CYP2C19CDC25AUSP2LMNA | |
| SCHEMBL22572509 | 0.87 | GPBAR1 (0.62) | USP2LMNAMEN1TP53KMT2A | |
| SCHEMBL1492167 | 0.87 | CYP2D6 (0.61) | CYP2D6CYP2C19INPP5DNPC1L1CDC25A | |
| SCHEMBL6064374 | 0.87 | GPBAR1 (0.56) | CDC25AUSP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | disclosed |
| US-10514383-B2 | Diagnosis and treatment of neonatal encephalopathy | INFANDX AG (DE) | 2019-12-24 | — | — | US | disclosed |
| US-20180011111-A1 | Method of Diagnosing and Treating Asphyxia | INFANDX AG (DE) | 2018-01-11 | — | — | US | disclosed |
| US-9791459-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2017-10-17 | — | — | US | disclosed |
| US-9085602-B1 | Facial amphiphiles and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140308687-A1 | Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy | INFANDX AG (DE) | 2014-10-16 | — | — | US | disclosed |
| EP-2771696-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | InfanDx AG (DE) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013060788-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2013-05-02 | — | — | WO | disclosed |
| EP-2587264-A1 | Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy | InfanDx AG (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-2529229-A1 | DIAGNOSING PROSTATE CANCER RELAPSE | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. (AT) | 2012-12-05 | — | — | EP | disclosed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | disclosed |
| WO-2011092286-A1 | DIAGNOSING PROSTATE CANCER RELAPSE | IMG INSTITUT FÜR MEDIZINISCHE GENOMFORSCHUNG PLANUNGSGESELLSCHAFT M.B.H. (AT) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011080184-A1 | USE OF ENDOGENOUS METABOLITES FOR EARLY DIAGNOSING SEPSIS | BIOCRATES LIFE SCIENCES AG (AT) | 2011-07-07 | — | — | WO | disclosed |
| EP-0813595-A1 | STIMULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996027658-A1 | STIMULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | CYP2D6 1097/4885CYP2C19 3083/4885INPP5D 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.